Description

• General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
• Application: PET Imaging in Lung Cancer: Fludeoxyglucose F18, used in PET scans, enhances the detection of occult lymph node metastases in lung cancer patients, offering significant improvements in diagnostic accuracy and patient management strategies (Guglielmo et al., 2023).Advanced Imaging Techniques: Research on time-of-flight (TOF) and non-TOF PET imaging explores the validation of reconstruction algorithms with NEMA phantoms, underscoring the critical role of Fludeoxyglucose in refining diagnostic approaches in clinical settings (Kumar et al., 2022).Fibroblast Activation Protein Inhibitor (FAPI) PET/CT Imaging: Non-oncologic incidental uptake studies using FAPI PET/CT imaging highlight Fludeoxyglucose′s versatility as a tracer that can potentially identify and characterize a variety of disease processes beyond its primary application in oncology (Hotta et al., 2023).Impact on HPV-related Cancer Diagnosis: Fludeoxyglucose is instrumental in imaging studies of human papilloma virus-associated oropharyngeal squamous cell carcinoma, aiding in the diagnosis and monitoring of this increasingly prevalent cancer, which is linked to significant morbidity and mortality rates (Touska et al., 2022).
• Analysis Note: These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​
• Other Notes: Sales restrictions may apply.